SCHEMBL7404355

SCHEMBL7404355

CC(C)C[C@H](Nc1nc(CN2CCN(c3ccccn3)CC2)ns1)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.45
ACE P12821 3/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CPT2 P23786 1/20 0.38
CPT1A P50416 1/20 0.38
HTR7 P34969 1/20 0.38
HTR1A P08908 2/20 0.37
LMNA P02545 2/20 0.37
DRD2 P14416 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7404341 1.00 ALDH1A1 (0.47) ALDH1A1KDM4ENPSR1HSD17B10ACE
SCHEMBL7598645 0.93 ALDH1A1 (0.46) ALDH1A1KDM4ENPSR1HSD17B10CPT2
SCHEMBL7400095 0.79 ACE (0.51) HSD17B10ACEMEN1KMT2ALMNA
SCHEMBL7402401 0.76 ACE (0.44) KDM4EHSD17B10ACEMEN1KMT2A
SCHEMBL7404249 0.74 ACE (0.42) KDM4EHSD17B10ACEMEN1KMT2A
SCHEMBL7447829 0.73 ACE (0.46) ALDH1A1KDM4ENPSR1HSD17B10ACE
SCHEMBL28746793 0.72 CNR2 (0.45) HSD17B10ACEMEN1KMT2ALMNA
SCHEMBL7644398 0.72 CNR2 (0.45) HSD17B10ACEMEN1KMT2ALMNA
SCHEMBL7640465 0.70 PEPD (0.38) ALDH1A1ACEMEN1KMT2ALMNA
SCHEMBL27556964 0.70 PEPD (0.38) ALDH1A1ACEMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6468977-B1 COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS APOTEX INC. (CA) 2002-10-22 US claimed
WO-2001090095-A1 THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES APOTEX INC. (CA) 2001-11-29 WO claimed
US-6162791-A Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes APOTEX INC. (CA) 2000-12-19 US claimed
EP-1058690-A1 THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES APOTEX INC. (CA) 2000-12-13 EP claimed
WO-1999045027-A1 THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES APOTEX INC. (CA) 1999-09-10 WO claimed
US-6468977-B1 COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS APOTEX INC. (CA) 2002-10-22 US disclosed
WO-2001090095-A1 THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES APOTEX INC. (CA) 2001-11-29 WO disclosed
US-6162791-A Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes APOTEX INC. (CA) 2000-12-19 US disclosed
EP-1058690-A1 THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES APOTEX INC. (CA) 2000-12-13 EP disclosed
WO-1999045027-A1 THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES APOTEX INC. (CA) 1999-09-10 WO disclosed